Literature DB >> 19358782

Management of common psychiatric conditions in the HIV-positive population.

Kelly Brogan1, Joseph Lux.   

Abstract

Presentation and management of psychiatric illness in HIV-infected patients can pose a challenge for clinicians. Psychiatric illness can exist premorbidly or result from the progression and treatment of HIV infection, influencing the course of the illness both through behavior and putative biological factors. Mood disorders, anxiety, psychosis, delirium, dementia, and substance abuse disorders all factor heavily into the care of HIV-infected patients. Management, however, continues to draw on small and skewed datasets, and remains largely an extrapolation from seronegative patient experience. The following is a discussion of treatment considerations derived from recent literature, as well as a consideration of judgments that clinicians may make in the absence of available data. The use of antidepressants, stimulants, mood stabilizers, and antipsychotics is discussed, as are precautions that must be taken with the HIV population when using these medications, not only because of side effect vulnerability, but because of significant drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358782     DOI: 10.1007/s11904-009-0016-x

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  49 in total

1.  Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.

Authors:  R Douglas Bruce; Frederick L Altice
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177

2.  Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial.

Authors:  J G Rabkin; G J Wagner; R Rabkin
Journal:  Am J Psychiatry       Date:  1999-01       Impact factor: 18.112

3.  Psychopathology of first-episode psychosis in HIV-positive persons in comparison to first-episode schizophrenia: a neglected issue.

Authors:  D De Ronchi; F Bellini; G Cremante; M Ujkaj; I Tarricone; R Selleri; R Quartesan; M Piselli; P Scudellari
Journal:  AIDS Care       Date:  2006-11

4.  A trial of integrated buprenorphine/naloxone and HIV clinical care.

Authors:  Lynn E Sullivan; Declan Barry; Brent A Moore; Marek C Chawarski; Jeanette M Tetrault; Michael V Pantalon; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

5.  Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients.

Authors:  A J Elliott; K K Uldall; K Bergam; J Russo; K Claypoole; P P Roy-Byrne
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112

6.  A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.

Authors:  W Breitbart; B Rosenfeld; M Kaim; J Funesti-Esch
Journal:  Arch Intern Med       Date:  2001-02-12

7.  Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women.

Authors:  Judith A Cook; Jane K Burke-Miller; Mardge H Cohen; Robert L Cook; David Vlahov; Tracey E Wilson; Elizabeth T Golub; Rebecca M Schwartz; Andrea A Howard; Claudia Ponath; Michael W Plankey; Alexandra M Levine; Andrea Levine; Dennis D Grey
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

8.  Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.

Authors:  C L Raison; B J Woolwine; M F Demetrashvili; A S Borisov; R Weinreib; J P Staab; J M Zajecka; C J Bruno; M A Henderson; J F Reinus; D L Evans; G M Asnis; A H Miller
Journal:  Aliment Pharmacol Ther       Date:  2007-05-15       Impact factor: 8.171

9.  Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome.

Authors:  Dwight L Evans; Kevin G Lynch; Tami Benton; Benoit Dubé; David R Gettes; Nancy B Tustin; Jian Ping Lai; David Metzger; Steven D Douglas
Journal:  Biol Psychiatry       Date:  2007-10-22       Impact factor: 13.382

10.  Relation of lifetime trauma and depressive symptoms to mortality in HIV.

Authors:  Jane Leserman; Brian Wells Pence; Kathryn Whetten; Michael J Mugavero; Nathan M Thielman; Marvin S Swartz; Dalene Stangl
Journal:  Am J Psychiatry       Date:  2007-11       Impact factor: 18.112

View more
  5 in total

1.  Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisons.

Authors:  Kenneth D Gadow; Konstantia Angelidou; Miriam Chernoff; Paige L Williams; Jerry Heston; Janice Hodge; Sharon Nachman
Journal:  J Dev Behav Pediatr       Date:  2012-07       Impact factor: 2.225

Review 2.  Neuropsychiatric Aspects of Infectious Diseases: An Update.

Authors:  Sahil Munjal; Stephen J Ferrando; Zachary Freyberg
Journal:  Crit Care Clin       Date:  2017-07       Impact factor: 3.598

Review 3.  Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment.

Authors:  Elyse J Singer; April D Thames
Journal:  Neurol Clin       Date:  2016-02       Impact factor: 3.806

Review 4.  Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era.

Authors:  Adriana Carvalhal; Jean-Guy Baril; Frederic Crouzat; Joss De Wet; Patrice Junod; Colin Kovacs; Nancy Sheehan
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

5.  Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database.

Authors:  Daniel J Ruzicka; Kentaro Imai; Kenichi Takahashi; Toshio Naito
Journal:  BMJ Open       Date:  2018-06-14       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.